{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:18:57Z","timestamp":1787750337797,"version":"build-2784847793"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>Etrasimod, a selective sphingosine-1-phosphate receptor modulator, is a new treatment for ulcerative colitis. This study aims to analyze the real-world distribution of adverse events (AEs) related to Etrasimod using the FDA Adverse Event Reporting System (FAERS) database, identify key AE signals, and provide a comprehensive safety assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>AE data related to Etrasimod from the FAERS database between Q4 2023 and Q1 2025 were analyzed using frequency-based and Bayesian methods, including reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and Empirical Bayesian Geometric Mean. Data from the FAERS were accessed on July 7, 2025. The authors did not have access to information that could identify individual participants during or after data collection, as FAERS provides only de-identified case reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>A total of 1284 AE reports were collected, of which 871 were Etrasimod related. Most reports (94.9%) came from the U.S. and primarily involved patients aged 18\u201365 (66.9%). The most common AEs were related to gastrointestinal disorders and general disorders, with \u201cDrug Ineffective\u201d and \u201cCondition Aggravated\u201d being prominent signals. Eye disorders, including diabetic eye disease and diabetic retinopathy (DR), were identified with high signal strength. New potential AEs such as Type 2 diabetes mellitus and diabetic eye disease were also identified. Severe events such as macular edema and blood cholesterol abnormal, although rare, showed high signal strength.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Etrasimod\u2019s safety risks primarily involve gastrointestinal issues, metabolic disorders, eye diseases, and reactions at the administration site. Most notably and unexpectedly, diabetes-related AEs constituted a prominent new safety signal, including type 2 diabetes, DR, and diabetic eye disease, and should be prioritized in early safety monitoring. Clinicians should monitor high-risk populations closely, especially in the early stages of treatment. Further research is needed to validate these findings and optimize safe use of Etrasimod.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_1209_25","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T18:00:25Z","timestamp":1782410425000},"page":"442-451","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive analysis of etrasimod-related adverse events based on the FDA Adverse Event Reporting System database"],"prefix":"10.4103","volume":"58","author":[{"given":"Zi-Ru","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Wuxi People\u2019s Hospital of Nanjing Medical University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Wuxi People\u2019s Hospital of Nanjing Medical University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Wuxi People\u2019s Hospital of Nanjing Medical University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Wuxi People\u2019s Hospital of Nanjing Medical University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Wuxi People\u2019s Hospital of Nanjing Medical University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Wuxi People\u2019s Hospital of Nanjing Medical University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"R1-20260626","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17474124.2021.1840976","article-title":"Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia","volume":"15","author":"Wei","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R2-20260626","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.3390\/jcm11092302","article-title":"An update on current pharmacotherapeutic options for the treatment of ulcerative colitis","volume":"11","author":"Ferretti","year":"2022","journal-title":"J Clin Med"},{"key":"R3-20260626","doi-asserted-by":"crossref","first-page":"107136","DOI":"10.1016\/j.ultsonch.2024.107136","article-title":"Ultrasound-assisted extraction of triterpenoids from Chaenomeles speciosa leaves: Process optimization, adsorptive enrichment, chemical profiling, and protection against ulcerative colitis","volume":"111","author":"Hou","year":"2024","journal-title":"Ultrason Sonochem"},{"key":"R4-20260626","doi-asserted-by":"crossref","first-page":"108775","DOI":"10.1016\/j.compbiomed.2024.108775","article-title":"Integrated metabolomics and serum-feces pharmacochemistry-based network pharmacology to reveal the mechanisms of an herbal prescription against ulcerative colitis","volume":"178","author":"Cheng","year":"2024","journal-title":"Comput Biol Med"},{"key":"R5-20260626","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","author":"Burr","year":"2021","journal-title":"Gut"},{"key":"R6-20260626","doi-asserted-by":"crossref","first-page":"7186","DOI":"10.3390\/jcm13237186","article-title":"Efficacy and safety of Janus kinase-inhibitors in ulcerative colitis","volume":"13","author":"Neri","year":"2024","journal-title":"J Clin Med"},{"key":"R7-20260626","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/17425255.2024.2402931","article-title":"Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis","volume":"20","author":"Vieujean","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R8-20260626","doi-asserted-by":"crossref","first-page":"807639","DOI":"10.3389\/fphar.2022.807639","article-title":"Molecular pharmacology and novel potential therapeutic applications of fingolimod","volume":"13","author":"Pournajaf","year":"2022","journal-title":"Front Pharmacol"},{"key":"R9-20260626","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40265-024-01997-7","article-title":"Etrasimod: First approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"R10-20260626","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S2468-1253(25)00062-7","article-title":"Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): A double-blind, placebo-controlled, randomised, phase 2 trial","volume":"10","author":"Dellon","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R11-20260626","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","article-title":"Mining and analysis of adverse event signals of cariprazine based on the real-world data of FAERS database","volume":"347","author":"Zhu","year":"2024","journal-title":"J Affect Disord"},{"key":"R12-20260626","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1038\/s41598-024-58460-6","article-title":"Analysis of post-market adverse events of istradefylline: A real-world study base on FAERS database","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci Rep"},{"key":"R13-20260626","first-page":"e20243879","article-title":"Potential adverse events of fluoxetine: A real-world study based on the FAERS database","volume":"47","author":"Gao","year":"2025","journal-title":"Braz J Psychiatry"},{"key":"R14-20260626","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jad.2024.03.085","article-title":"Multidimensional assessment of adverse events of bupropion: A large-scale data analysis from the FAERS database","volume":"354","author":"Lu","year":"2024","journal-title":"J Affect Disord"},{"key":"R15-20260626","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jad.2024.07.103","article-title":"Comprehensive analysis of adverse events associated with pimavanserin using the FAERS database","volume":"362","author":"Gu","year":"2024","journal-title":"J Affect Disord"},{"key":"R16-20260626","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jad.2025.01.022","article-title":"Characteristics of adverse events and clinical risks of lecanemab based on FAERS data","volume":"374","author":"Li","year":"2025","journal-title":"J Affect Disord"},{"key":"R17-20260626","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00406-023-01732-5","article-title":"The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database","volume":"275","author":"Jiang","year":"2025","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R18-20260626","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of brexpiprazole: Real-world adverse event analysis from the FAERS database","volume":"346","author":"Jiang","year":"2024","journal-title":"J Affect Disord"},{"key":"R19-20260626","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12888-024-05813-0","article-title":"Exploring adverse events of vilazodone: Evidence from the FAERS database","volume":"24","author":"Jiang","year":"2024","journal-title":"BMC Psychiatry"},{"key":"R20-20260626","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: Implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"R21-20260626","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R22-20260626","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R23-20260626","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R24-20260626","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"issue":"Suppl 1","key":"R25-20260626","doi-asserted-by":"crossref","first-page":"i416","DOI":"10.1093\/ecco-jcc\/jjad212.0257","article-title":"P127 sphingosine-1-phosphate receptor blockade with etrasimod alters lymphocyte trafficking in Crohn's disease: Insights from high-dimensional phenotypic mapping","volume":"18","author":"Nikolakis","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R26-20260626","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"R27-20260626","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/ecco-jcc\/jjae060","article-title":"Etrasimod for the treatment of ulcerative colitis: Analysis of infection events from the elevate UC clinical programme","volume":"18","author":"Regueiro","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R28-20260626","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000541383","article-title":"Efficacy and safety of etrasimod in patients with ulcerative colitis in Japan: Data from the phase 3 elevate UC 12 and elevate UC 40 Japan trials","volume":"106","author":"Takeuchi","year":"2025","journal-title":"Digestion"},{"key":"R29-20260626","doi-asserted-by":"crossref","first-page":"e07564","DOI":"10.1016\/j.heliyon.2021.e07564","article-title":"Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as novel risk markers for diabetic nephropathy in patients with type 2 diabetes","volume":"7","author":"Jaaban","year":"2021","journal-title":"Heliyon"},{"key":"R30-20260626","doi-asserted-by":"crossref","first-page":"927768","DOI":"10.3389\/fcvm.2022.927768","article-title":"Predictive value of non-high-density lipoprotein cholesterol and neutrophil-lymphocyte ratio for coronary artery vulnerable plaques in type 2 diabetes mellitus","volume":"9","author":"Huang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R31-20260626","doi-asserted-by":"crossref","first-page":"6493","DOI":"10.3390\/ijms22126493","article-title":"Hepcidin-ferroportin interaction controls systemic iron homeostasis","volume":"22","author":"Nemeth","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R32-20260626","doi-asserted-by":"crossref","first-page":"112219","DOI":"10.1016\/j.intimp.2024.112219","article-title":"Interferon-induced polarization of M1 macrophages mediates antiviral activity against the hepatitis B virus via the hepcidin-ferroportin axis","volume":"134","author":"Liu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R33-20260626","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.3390\/ijms22094411","article-title":"Targeting S1PRs as a therapeutic strategy for inflammatory bone loss diseases-beyond regulating S1P signaling","volume":"22","author":"Yu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R34-20260626","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1136\/bjophthalmol-2021-319115","article-title":"Sphingosine 1-phosphate, a potential target in neovascular retinal disease","volume":"106","author":"Alshaikh","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R35-20260626","doi-asserted-by":"crossref","first-page":"907396","DOI":"10.3389\/fendo.2022.907396","article-title":"CD8+T cell-related gene biomarkers in macular edema of diabetic retinopathy","volume":"13","author":"Huang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_1209_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:25:54Z","timestamp":1787747154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_1209_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_1209_25","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2025-11-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}